Shanghai Pharmaceuticals (601607) Q3 2026 earnings summary

Executive summary

• 9M 2026 revenue rose 3.67% YoY to RMB 222.96bn; net profit attributable to shareholders fell 10.90% to RMB 4.59bn, while adjusted net profit rose 25.02%.

• Operating cash flow increased 127.54% YoY to RMB 5.35bn, supported by higher cash receipts from sales and services.

Financial highlights

• Q3 revenue was RMB 75.49bn, up 2.74% YoY; attributable net profit was RMB 1.08bn, up 57.15%, and adjusted attributable profit was RMB 897m, up 49.69%.

• 9M total profit was RMB 7.56bn, down 8.94% YoY; net profit was RMB 5.77bn versus RMB 5.99bn a year earlier.

• 9M non-recurring gains totaled RMB 1.21bn, including RMB 1.19bn from disposal of non-current assets; adjusted attributable net profit was RMB 3.37bn.

• Total assets reached RMB 242.05bn at Sep. 30, up 3.82% from year-end 2025; attributable equity rose 4.55% to RMB 79.34bn.

Outlook and guidance

• Strategy prioritizes innovation-drug lifecycle services, CSO and SPD offerings, medical-device and health services, new retail, and digital transformation to support continued growth.

• Plans include building an integrated specialist-pharmacy network and expanding innovation partnerships across the pharmaceutical supply chain and payment ecosystem.